Attachment
A number of cytotoxic drugs are on the market, however only a few currently dominate in terms of revenues, with Taxotere (docetaxel; Sanofi-Aventis)
Despite undergoing patent expiry during the forecast period, Taxotere and Eloxatin and Dacogen (decitabine;
However, the increasingly competitive nature of the market has raised significant barriers to entry and any new product will need to show superiority over the competition.
This Datamonitor report Commercial Insight - Cytotoxic Therapies analyzes the current and future potential of the cytotoxic therapies market. It includes sales forecasts to 2018 across the seven major pharmaceutical markets (7MM), taking into account the key events predicted to influence product revenues, such as the launch of new drugs, expansion of existing drugs into new indications and patent expiries.
This comprehensive report offers:
• An in-depth analysis of the current and future cytotoxic therapies market across the US, 5EU and Japan, plus a rest of world snapshot.
• Cytotoxic therapy sales forecasts for brands and generics from 2008 to 2018.
• An assessment of the leading cancer brands and drug classes, designed to help identify key success factors within this sector.
• An analysis of the strategies of several leading players in the cytotoxics market.
To purchase this Datamonitor report Commercial Insight: Cytotoxic Therapies please contact:
reports-research.com
c/o dynamic technologies GmbH
Siegburger Str. 233
50679 Köln
Germany
Manuel Bravo Sanchez (CEO)
info@reports-
or
Tel ++49 (0)221 690 688 55
Fax ++49 (0)221 690 688 56
Datamonitor:
http://www.reports-
Photo:
http://www.prlog.org/
